The DOI matches its Crossref record.
Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 26
- Hickey, 2005, Management of menopausal symptoms in patients with breast cancer: an evidence-based approach, Lancet Oncol, 6, 687, 10.1016/S1470-2045(05)70316-8 · DOI
- Holmberg, 2004, HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped, The Lancet, 363, 453, 10.1016/S0140-6736(04)15493-7 · DOI · Paper page
- von Schoultz, 2005, Menopausal hormone therapy after breast cancer: The Stockholm randomized trial, J Natl Cancer Inst, 97, 533, 10.1093/jnci/dji071 · DOI · Paper page
- Holmberg, 2008, Increased risk of recurrence after hormone replacement therapy in breast cancer survivors, J Natl Cancer Inst, 100, 475, 10.1093/jnci/djn058 · DOI · Paper page
- Clark, 2002, Quantification of the completeness of follow-up, The Lancet, 359, 1309, 10.1016/S0140-6736(02)08272-7 · DOI · Paper page
- Prentice, 1978, The analysis of failure times in the presence of competing risks, Biometrics, 34, 541, 10.2307/2530374 · DOI · Paper page
- DiSaia, 2000, Breast cancer survival and hormone replacement therapy: a cohort analysis, Am J Clin Oncol, 23, 541, 10.1097/00000421-200012000-00001 · DOI
- Xydakis, 2006, Hormone replacement therapy in breast cancer survivors, Ann NY Acad Sci, 1092, 349, 10.1196/annals.1365.032 · doi:10.1196/annals.1365.032
- Col, 2005, Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence, Breast Cancer Res, 7, R535, 10.1186/bcr1035 · DOI
- Batur, 2006, Menopausal hormone therapy (HT) in patients with breast cancer, Maturitas, 53, 123, 10.1016/j.maturitas.2005.03.004 · DOI
- Santen, 2010, Postmenopausal hormone therapy: an Endocrine Society Scientific Statement, J Clin Endocrinol Metab, 95, S1, 10.1210/jc.2009-2509 · DOI · Paper page
- Kenemans, 2009, Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised non-inferiority trial, Lancet Oncol, 10, 135, 10.1016/S1470-2045(08)70341-3 · DOI · Paper page
- Fournier, 2009, Estrogen-progestogen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risk?, J Clin Oncol, 27, 5138, 10.1200/JCO.2008.21.6432 · DOI
- Beral, 2011, Breast cancer risk in relation to the interval between menopause and starting hormone therapy, J Natl Cancer Inst, 103, 296, 10.1093/jnci/djq527 · DOI · Paper page
- Song, 2005, Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells, Apoptosis, 10, 667, 10.1007/s10495-005-1903-2 · DOI
- Lewis, 2005, Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation, J Natl Cancer Inst, 97, 1746, 10.1093/jnci/dji400 · DOI · Paper page
- Schairer, 2000, Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk, JAMA, 283, 485, 10.1001/jama.283.4.485 · DOI · Paper page
- Collins, 2005, Breast cancer risk with postmenopausal hormone treatment, Hum Reprod Update, 11, 545, 10.1093/humupd/dmi028 · DOI · Paper page
- Prentice, 2008, Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative clinical trial and observational study, Am J Epidemiol, 167, 1407, 10.1093/aje/kwn090 · DOI
- Conner, 2008, Breast cancer and hormonal therapy, Clin Obstet Gynecol, 51, 592, 10.1097/GRF.0b013e318180b8ed · DOI
- Swedish Breast Cancer Cooperative Group, 1996, Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early-stage breast cancer, J Natl Cancer Inst, 88, 1543, 10.1093/jnci/88.21.1543 · DOI · Paper page
- 1998, Tamoxifen for early breast cancer: an overview of the randomized trials, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4 · DOI · Paper page
- Osborne, 2009, The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer, Breast Cancer Res Treat, 116, 521, 10.1007/s10549-008-0284-y · DOI
- Sestak, 2006, Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms, J Clin Oncol, 24, 3991, 10.1200/JCO.2005.04.3745 · DOI
- Fahlén, 2011, Health-related quality of life during hormone therapy after breast cancer: a randomized trial, Climacteric, 14, 164, 10.3109/13697131003660593 · DOI
- Marsden, 2000, Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?, Fertil Steril, 73, 292, 10.1016/S0015-0282(99)00510-5 · DOI
Cited by
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Risk Factors and Preventions of Breast Cancer
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21635 · Cited by 2,003
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“Nevertheless, the final decision belongs to the patient, after adequate information, since in some cases these symptoms are impacting significantly onQoL.(111,112) For menopausal symptoms in general, mind-body interventions, physical training and cognitive behavioural therapy should be recommended as effective non-pha…”
BackgroundThe 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Maas, A. H. E. M., Rosano, G., Cifkova, R., Chieffo, A., van Dijken, D., Hamoda, H., Kunadian, V., Laan, E., Lambrinoudaki, I., Maclaran, K., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1044 · Cited by 344
Metabolic shifts in residual breast cancer drive tumor recurrence
Havas, K. M., Milchevskaya, V., Radic, K., Alladin, A., Kafkia, E., Garcia, M., Stolte, J., Klaus, B., Rotmensz, N., Gibson, T. J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89914 · Cited by 168
HRT for women with premature ovarian insufficiency: a comprehensive review
Webber, L., Anderson, R. A., Davies, M., Janse, F., & Vermeulen, N. (2017) · Human Reproduction Open · doi:10.1093/hropen/hox007 · Cited by 141
The pharmacological and hormonal therapy of hot flushes in breast cancer survivors
Wiśniewska, I., Jochymek, B., Lenart-Lipińska, M., & Chabowski, M. (2016) · Breast Cancer · doi:10.1007/s12282-015-0655-2 · Cited by 36
Metadata
- Authors
- Fahlén, M., Fornander, T., Johansson, H., Johansson, U., Rutqvist, L.-E., Wilking, N., & von Schoultz, E.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 49
- Issue
- 1
- Pages
- 52-59
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2121476566
- Cited by
- 158
- References
- 0
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Stockholm Cancer Society
- King Gustav V Jubilee Fund
- Stockholm County Council
- Karolinska Institutet
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.